Pictet sees China biotech opportunities driving greater Asia exposure
The firm could allocate around 10% to Asia, with the share potentially rising depending on opportunities.
Share this signal
Nvdium209 published todayNvdium209 published todayThe firm could allocate around 10% to Asia, with the share potentially rising depending on opportunities.